Calvenza EIV/EHV (Canada)

Company: Boehringer Ingelheim Animal Health

Equine Rhinopneumonitis-Influenza Vaccine

Killed Virus

Calvenza EIV/EHV Indications

This product has been shown to be effective for the vaccination of healthy horses 6 months of age or older, including pregnant mares, against respiratory disease due to equine herpesvirus types 1 and 4 (EHV-1 & EHV-4), and equine influenza virus (EIV) types A2 North American and A2 Eurasian. The duration of immunity has not been determined. For more information regarding efficacy and safety data go to productdata.aphis.usda.gov.

Composition

Contains Kentucky Lineage (KY/95), Florida sublineage clade 1 (OH/03), and Eurasian Newmarket/2/93 (NM 2/93) EIV strains. Gentamicin and thimerosal added as preservatives.

Directions and dosage: Shake well before use. Using aseptic technique, vaccinate horses intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3 to 4 weeks using a different injection site. Administer a third 2 mL dose in 3 to 4 weeks by either the intramuscular or intranasal route. The need for annual booster vaccinations has not been established for this product; consultation with a veterinarian is recommended.

Precautions

Store at 2-8°C. Do not freeze. Do not mix with other products. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Transient local reactions may occur at the injection site. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician.

For use in animals only.

Calvenza^® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., St. Joseph, MO 64506

Tel: 1 (888) 637-4251

VLN/PCN 124/1515.2A

Distributed by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

CPN: 1182190.1